KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Asset Writedowns and Impairment (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 11 years of Asset Writedowns and Impairment data on record, last reported at $4.6 million in Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment rose 128.82% year-over-year to $4.6 million; the TTM value through Dec 2025 reached $986000.0, down 67.48%, while the annual FY2025 figure was $986000.0, 67.48% down from the prior year.
  • Asset Writedowns and Impairment reached $4.6 million in Q4 2025 per IONS's latest filing, up from -$3.9 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $4.6 million in Q4 2025 and bottomed at -$3.9 million in Q3 2025.
  • Average Asset Writedowns and Impairment over 5 years is $528850.0, with a median of $326500.0 recorded in 2021.
  • Peak YoY movement for Asset Writedowns and Impairment: skyrocketed 1736.36% in 2021, then tumbled 735.48% in 2025.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $1.6 million in 2021, then tumbled by 43.8% to $875000.0 in 2022, then grew by 11.2% to $973000.0 in 2023, then skyrocketed by 107.91% to $2.0 million in 2024, then soared by 128.82% to $4.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $4.6 million in Q4 2025, -$3.9 million in Q3 2025, and $236000.0 in Q2 2025.